Steven J. Prestrelski

Steve Prestrelski is a distinguished scientific leader with extensive experience in the biopharmaceutical industry. Currently serving as Chief Scientific Officer at MBX Biosciences, Inc. since July 2023, Steve has also held critical roles at Xeris Pharmaceuticals, Inc. from January 2011, including Senior Scientific Advisor, Chief Scientific Officer, and Chief Executive Officer. Steve's previous positions include Vice-President of Pharmaceutical R&D at Amylin Pharmaceuticals, where responsibilities encompassed leading the Bydureon program and managing significant operational expenses and capital investments. With past contributions in R&D leadership and advisory roles at various organizations, including AlgoRx Technologies and PowderJect Technologies, Steve has developed and implemented successful drug delivery technologies and strategies. Steve holds an MBA from the University of California, San Diego, a PhD in Biomedical Science from The City University of New York, and a BS in Nutrition Science from Drexel University.